No Data
No Data
Wells Fargo Maintains Bicara Therapeutics(BCAX.US) With Sell Rating, Maintains Target Price $8
Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), AstraZeneca (AZN)
Bicara Therapeutics Says Updated Data From Ongoing Phase 1/1b Clinical Trial Of Ficerafusp Alfa In 1L R/M HNSCC To Be Highlighted In Oral Presentation At 2025 ASCO Annual Meeting
Wells Fargo Initiates Bicara Therapeutics(BCAX.US) With Sell Rating, Announces Target Price $8
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target